Brazil’s antitrust watchdog Cade is due to reveal on Wednesday whether HSBC Holdings Plc can sell its Brazilian unit to Banco Bradesco SA, a decision with big implications for the British bank’s Chief Executive Officer Stuart Gulliver and shareholders.
Gulliver is counting on the $5.2 billion sale of HSBC Bank Brasil Banco Múltiplo SA to boost HSBC’s main capital ratio and ensure the bank remains the biggest dividend payer among European banks. Some analysts fear the bank may fail to maintain its payout if the unit’s sale is delayed.
“This deal is important because it adds 60 basis points to HSBC’s capital strength which gets them to their target and means they can maintain the dividend in a weak year for earnings,” said Ian Gordon, an analyst at Investec.
Brazil’s central bank has already approved the deal, HSBC’s biggest single asset sale since pledging to shrink its sprawling global business to cut costs and boost profits.
Yet, watchdog Cade has clashed with the central bank in the past over their roles in supervising M&A in banking. Both said they have jurisdiction over the financial sector based on their interpretation of the law. The issue is currently being analyzed by Brazil’s Supreme Federal Court.
Cade has been reviewing Bradesco’s purchase since February and has so far failed to reach a consensus among its directors that competition will not be affected, a source familiar with the discussions told Reuters. The watchdog’s scrutiny of the deal is taking place as Brazil wrestles with the impact of a harsh recession and a sweeping political crisis.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas